James Stapleton’s Post

Each year in the United States, 185,000 individuals experience recurrent strokes. (1) 😱 Let's not just scroll past this number. Let's take action! Spread awareness, learn the warning signs, and prioritize preventive care. Every step counts in the fight against strokes! 💪💙 Find out how the rapid Genomadix CYP2C19 test can help optimize DAPT treatment to reduce recurrent stroke rates at www.genomadixcom (2,3)🧬#StrokeAwareness #PersonalizedMedicine #Pharmacogenetics 1. Kleindorfer DO, et al. Stroke. 2021;52:e364–e467. 2. Wang Y, et al. N Engl J Med. 2021;385:2520-2530. 3. Lee CR, et al. J Clinical Pharmacol Therapeutics. 2022;122(5):959-967.

🚀 BioVie’s Investor Webinar Today at 4:15 PM ET! 🚀 Join us to explore BioVie’s game-changing drug therapies targeting Alzheimer’s, Parkinson’s, Long COVID, and advanced liver disease. Don’t miss this deep dive into BioVie’s upcoming clinical milestones and strategic vision! 🔗 Register here 👉 https://lnkd.in/dGkuHHTt #FDA #Biotech #BioVie #ParkinsonsDisease #Alzheimers #ClinicalTrials #FinancialNews #CapitalMarkets

What if you could get liver safety predictions in the discovery stage? De-risking clinical hepatotoxicity early in the drug development process has never been possible—until now. In this webinar, attendees will learn how to use the only available software equipped to make clinically relevant liver safety predictions, permissive for early and later-stage drug discovery applications, involving multiple DILI mechanisms: oxidative stress, mitochondrial dysfunction, and inhibition of bile acid and phospholipid transporters. https://lnkd.in/giFTbrcH

From the AMMG E-Journal, ‘It’s Big-Time Progress’: Groundbreaking Alzheimer’s Drug: https://bit.ly/3T35N8r. "The medication, Leqembi, a monoclonal antibody manufactured by Eisai and Biogen, is the first to reduce the amount of amyloid beta plaque in the brain, slowing down the progression of the illness. Though it can’t reverse the damage already done by Alzheimer’s disease, it can produce improvement for patients with mild symptoms, research has shown." #AlzheimersTreatment #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences

Join me and my co-workers to hear how our new ADMET Predictor DILIsym module can be used to assess hepatotoxic risk in early drug discovery!

What if you could get liver safety predictions in the discovery stage? De-risking clinical hepatotoxicity early in the drug development process has never been possible—until now. In this webinar, attendees will learn how to use the only available software equipped to make clinically relevant liver safety predictions, permissive for early and later-stage drug discovery applications, involving multiple DILI mechanisms: oxidative stress, mitochondrial dysfunction, and inhibition of bile acid and phospholipid transporters. https://lnkd.in/giFTbrcH

In case you missed it, we have just launched our new advanced lung FMT assay 🫁 The advanced high-throughput high-sensitivity lung FMT assay facilitates customisable and rapid assessment of the efficacy of anti-fibrotic drug candidates. Building on the success of our existing FMT assay, this advanced version provides data at higher-resolution, with simultaneous assessment of four separate data outputs for more accurate selection and predictivity of drug effects on pulmonary fibrosis. Find out more 👉 https://lnkd.in/ePdxzcZm #Newcells #DrugDevelopment #FMT #LungAssay

Cough in IPF can be triggered by countless factors, making daily life exceptionally tough. At Trevi Therapeutics, we are committed to our research in chronic cough. Learn more about Trevi’s development in chronic cough: https://ow.ly/k7nV50TzELV #ChronicCough #CoughinIPF #Pulmonary Fibrosis #IdiopathicPulmonaryFibrosis

At #ACC24, Novo Nordisk presented full data from the STEP HFpEF-DM study on their glucagon-like peptide 1 (GLP-1) receptor agonist, semaglutide, for the treatment of #obesity. The trial demonstrated semaglutide was superior to placebo for driving reductions in body weight and patient-oriented quality-of-life improvements in heart failure symptoms after 52 weeks of treatment. Together with their other STEP series of studies, the data shows benefits beyond weight loss, extending to improvements in cardiovascular health and implying potential for far reaching health benefits as applications for these therapies evolve. To learn more, please read our detailed article at: https://lnkd.in/emP2e5E7 For more information contact: Kyasha Sri Ranjan, PhD, Austin Jeffries, PhD and Chris Onderisin, PhD #NovoNordisk #Eli Lilly #Amgen #AstraZeneca #StructureTherapeutics #VikingTherapeutics #Pfizer #ACC24

A letter to the editor by Papp, et al. presents the results of a Phase 4, 26-week, open label investigation of brodalumab in patients with psoriasis and an inadequate responses to another biologic. They found that brodalumab can be beneficial in patients failing to respond to TNF-α, IL-12/23, or IL-17 inhibitors. You can find the full paper summary on the #IMIDForum, completely free, along with the latest updates in #Psoriasis https://ow.ly/eeBE50Svlhf